🇺🇸 FDA
Pipeline program

Immunomodulatory DC vaccines to target prostate cancer

GIMI-IRB-25002

Phase 2 mab active

Quick answer

Immunomodulatory DC vaccines to target prostate cancer for Prostate Cancer Indications is a Phase 2 program (mab) at Shenzhen Second People's Hospital with 1 ClinicalTrials.gov record(s).

Program details

Company
Shenzhen Second People's Hospital
Indication
Prostate Cancer Indications
Phase
Phase 2
Modality
mab
Status
active

Clinical trials